ketamine
Spotlight: Efficacy and safety of ketamine maintenance therapy in treatment-resistant depression: A systematic review of treatment protocols and clinical outcomes (Al-Garni, et al, 2025)
"Concurrent psychotherapy improved treatment maintenance. Adverse events were generally mild to moderate... Ketamine maintenance therapy shows promise as a treatment option for TRD, with regular dosing schedules and early intervention associated with optimal outcomes."
ketamine
Spotlight: Oral ketamine for the treatment of major depressive and bipolar disorder, a randomized controlled trial and meta-analysis (Silberbauer, et al, 2025)
Treatment was well-tolerated, with no serious adverse events reported...in a total of 592 patients, meta-analysis of randomized controlled trials on oral ketamine treatment demonstrated its antidepressant efficacy with a Number Needed to Treat = 4.89 for response and a NNT = 9.16 for remission.
at home ketamine
Spotlight: Real-world clinical data on the long-term effectiveness and safety of generic racemic ketamine treatment (Massaneda-Tuneu, et al, 2025)
"Findings suggested that racemic ketamine (including by mouth), when appropriately dosed and administered within a structured clinical and safety monitoring framework, is both effective, safe and well-tolerated over a 6-month treatment period."
ketamine
Spotlight: Synaptic priming: A framework for pharmacotherapy in depression (Brown, et al, 2025)
"we describe how the indirect relationship between ketamine's pharmacokinetics and sustained antidepressant pharmacodynamics reveals a dosing model (primer pharmacology) that can be harnessed to fine-tune therapeutic outcomes."
at home ketamine
Spotlight: Ketamine Harm Reduction
Prevention & Treatment in Ketamine Use Disorder - When a medicine becomes a poison
iv ketamine
Spotlight: First study to compare two ketamine therapies for patients with severe depression
IV ketamine found to offer faster response with greater improvements than FDA-approved intranasal esketamine (Spravato)
ketamine
Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population (Hughes, et al, 2025)
"Ketamine's use for pediatric TRD demonstrated rapid-onset relief for signs and symptoms of depression in children and adolescents, and psilocybin also decreased symptoms in patients with longstanding or refractory depression. Ketamine has been well tolerated and exhibited symptom improvements"
ketamine
Spotlight: Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis (Bhatt, et al, 2025)
Experiencia mística de la ketamina en veteranos con depresión resistente en tratamiento: un análisis exploratorio retrospectivo
ketamine repeated doses
Spotlight: Comparing the Cognitive Effects of Repeated Intravenous Ketamine and Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Secondary Analysis of the ELEKT-D Trial
"Patients treated with ketamine demonstrated superior cognitive functioning compared with ECT following a 3-week treatment, no differences between treatments observed. Findings support short-term superiority of ketamine on cognitive functioning and the long-term cognitive safety of both treatments."
ketamine
Spotlight: A retrospective analysis of ketamine intravenous therapy for post-traumatic stress disorder in real-world care settings (McInnes, et al, 2025)
"In a large real-world sample of 8,136 PTSD patients (87 % with comorbid depression), Ketamine Intravenous Therapy (KIT) significantly reduced PTSD and depression symptoms."
ketamine
Spotlight: The association between amygdalar volume changes and depressive symptom improvements after repeated ketamine infusion in treatment-resistant depression (2025)
"The reductions in right LB volumes correlate with better clinical responses to ketamine in patients with TRD, suggesting ketamine may exert its effect by attenuating amygdalar overactivity in this population."
ketamine
Spotlight: Real world effectiveness of maintenance ketamine infusions for treatment-resistant depression in major depressive disorder and bipolar disorder (Haikazian, et al, 2025)
"Ketamine was determined to be relatively safe, with zero cases of suicidal behaviour and addiction behaviour throughout treatment."
